Alnylam stages a comeback with positive late-stage study results for RNAi treatment Patisiran
Promising Phase 3 study results for its RNAi treatment, called Patisiran, for a rare, genetic nerve disorder have increased the chances that Alnylam could be the first to commercialize a RNAi drug.